Final results of phase III SYMMETRY study: Randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma

Steven J. O'Day*, Alexander M M Eggermont, Vanna Chiarion-Sileni, Richard Kefford, Jean Jacques Grob, Laurent Mortier, Caroline Robert, Jacob Schachter, Alessandro Testori, Jacek Mackiewicz, Philip Friedlander, Claus Garbe, Selma Ugurel, Frances Collichio, Wei Guo, Joelle Lufkin, Safi Bahcall, Vojo Vukovic, Axel Hauschild

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

75 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Final results of phase III SYMMETRY study: Randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences